Search
Home
News
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Coins2Day 500
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Laura Lorenzetti
Stay informed with Laura Lorenzetti’s coverage and analysis for Coins2Day.
Page 39 of 73
Tech
Jawbone sues Fitbit over secret-stealing allegations
By
Editorial Team
Ford’s Zipcar-killer is launching in this city
By
Senior Editor
Retail
These are the 2 big changes McDonald’s is making to its burgers
By
Investment Desk
Features
How your cell phone knows if you’ve been laid off
By
Market Analyst
Retail
McDonald’s won’t reveal this key data any longer
By
Investment Desk
Tech
These are the 8 most valuable brands
By
News Correspondent
Features
FX probe settlements and Target’s turnaround–5 things to know today
By
Laura Lorenzetti
and
Geoffrey Smith
Features
ECB peps markets and JPMorgan shareholders vote on Dimon’s pay–5 things to know today
By
Staff Writer
MPW
Meet the women who put words in Don Draper’s mouth
By
Investment Desk
Features
Eurozone GDP, and Dupont shareholders vote — 5 things to know today
By
Laura Lorenzetti
and
Geoffrey Smith
Features
Verizon buys AOL, and a Picasso record — 5 things to know today
By
Laura Lorenzetti
and
Geoffrey Smith
Finance
Biopharma deals are booming this year with no end in sight
By
Research Team
Features
Cancer drug spending hit $100 billion in 2014. Here’s why it’ll soon be much higher
By
Investment Desk
Features
Bud finds favor, and the EU looks at big tech — 5 things to know today
By
Blockchain Reporter
Tech
Walt Disney beats expectations even as it faces a Frozen comedown
By
Blockchain Reporter